Michael Pellini

Michael Pellini

Director/Board Member chez SINGULAR GENOMICS SYSTEMS, INC.

Fortune : 359 557 $ au 31/03/2024

58 ans
Health Services
Health Technology
Commercial Services

Profil

Mike is a Managing Partner of S32, a venture capital fund investing at the frontiers of technology and healthcare.
Prior to joining S32 in 2017, he served as CEO of Foundation Medicine, a company which transformed the way pharmaceutical companies and physicians evaluate the genomic changes underlying a patient’s cancer, until he transitioned to Chairman through the close of Roche’s (RHHBY) acquisition of FMI in August 2018.
Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010.
He currently serves as a member of the Board of Directors for Nusano, Singular Genomics (OMIC), Adaptive Biotechnologies (ADPT), Octave BioSciences, TwinStrand Genomics, the Personalized Medicine Coalition, and the American Cancer Society.
He previously served on the board of Thrive Earlier Detection, which was acquired by Exact Sciences (EXACT) in 2021, and Tango Therapeutics (TNGX).
Mike brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer.
He is also a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health.
During the COVID pandemic, Mike served as a Senior Advisor to the Rockefeller Foundation’s efforts on COVID-19 testing.
Mike received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
25/05/2023 351 222 ( 0,48% ) 180 528 $ 31/03/2024
04/03/2024 54 296 ( 0,04% ) 174 290 $ 31/03/2024
15/10/2022 519 ( 0,00% ) 4 738 $ 31/03/2024

Postes actifs de Michael Pellini

SociétésPosteDébut
ADAPTIVE BIOTECHNOLOGIES CORPORATION Director/Board Member 13/02/2018
SINGULAR GENOMICS SYSTEMS, INC. Director/Board Member 01/04/2017
Private Equity Investor 01/12/2017
Director/Board Member 01/01/2023
Director/Board Member -
Director/Board Member -
Go2 Foundation For Lung Cancer Director/Board Member -
Director/Board Member -
Director/Board Member -
░░░░░░ ░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ -
░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Tous les postes actifs de Michael Pellini

Anciens postes connus de Michael Pellini

SociétésPosteFin
░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Michael Pellini

Formation de Michael Pellini

Drexel University Masters Business Admin
Boston College Undergraduate Degree
Sidney Kimmel Medical College Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Michael Pellini

Relations

100 +

Relations au 1er degré

31

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées4
SAFEGUARD SCIENTIFICS, INC.

Finance

ADAPTIVE BIOTECHNOLOGIES CORPORATION

Health Technology

SINGULAR GENOMICS SYSTEMS, INC.

Health Technology

GENEDX HOLDINGS CORP.

Health Services

Entreprise privées23

Health Services

Health Technology

Health Technology

Commercial Services

Finance

Health Services

Mission Hospital Foundation

Commercial Services

Commercial Services

Commercial Services

Health Services

Health Services

Health Services

Health Technology

Health Technology

Finance

Health Services

Health Technology

Commercial Services

Health Services

Health Technology

Go2 Foundation For Lung Cancer

Technology Services

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Michael Pellini